Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
October 14, 2020 17:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
September 17, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
- Maintained 34% objective response rate and 79% disease control rate, including two complete responses - XMT-1536 continues to be generally well-tolerated with no new safety signals - Data...
Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress
September 10, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
- Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Mersana...
Mersana Therapeutics to Present at Upcoming Investor Conferences
September 03, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2020 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs
August 31, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer
August 11, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update
August 07, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
- Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate...
Mersana Therapeutics to Present at Upcoming Investor Conferences
August 04, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates
July 31, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...